Suppr超能文献

人类甲状腺癌中的PAX8-PPARγ1融合癌基因[已修正]

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

作者信息

Kroll T G, Sarraf P, Pecciarini L, Chen C J, Mueller E, Spiegelman B M, Fletcher J A

机构信息

Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

出版信息

Science. 2000 Aug 25;289(5483):1357-60. doi: 10.1126/science.289.5483.1357.

Abstract

Chromosomal translocations that encode fusion oncoproteins have been observed consistently in leukemias/lymphomas and sarcomas but not in carcinomas, the most common human cancers. Here, we report that t(2;3)(q13;p25), a translocation identified in a subset of human thyroid follicular carcinomas, results in fusion of the DNA binding domains of the thyroid transcription factor PAX8 to domains A to F of the peroxisome proliferator-activated receptor (PPAR) gamma1. PAX8-PPARgamma1 mRNA and protein were detected in 5 of 8 thyroid follicular carcinomas but not in 20 follicular adenomas, 10 papillary carcinomas, or 10 multinodular hyperplasias. PAX8-PPARgamma1 inhibited thiazolidinedione-induced transactivation by PPARgamma1 in a dominant negative manner. The experiments demonstrate an oncogenic role for PPARgamma and suggest that PAX8-PPARgamma1 may be useful in the diagnosis and treatment of thyroid carcinoma.

摘要

编码融合癌蛋白的染色体易位在白血病/淋巴瘤和肉瘤中一直被观察到,但在最常见的人类癌症——癌中却未被观察到。在此,我们报告在一部分人类甲状腺滤泡癌中发现的t(2;3)(q13;p25)易位,导致甲状腺转录因子PAX8的DNA结合结构域与过氧化物酶体增殖物激活受体(PPAR)γ1的A至F结构域融合。在8例甲状腺滤泡癌中的5例检测到PAX8-PPARγ1 mRNA和蛋白,但在20例滤泡性腺瘤、10例乳头状癌或10例多结节性增生中未检测到。PAX8-PPARγ1以显性负性方式抑制噻唑烷二酮诱导的PPARγ1反式激活。这些实验证明了PPARγ的致癌作用,并表明PAX8-PPARγ1可能在甲状腺癌的诊断和治疗中有用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验